HOME >> MEDICINE >> NEWS
Alzheimer's drug improves pilots' performance on tests

St. Paul, MN A drug that boosts memory for Alzheimer's patients may also augment the performance of airplane pilots, according to a study published in the July 9 issue of Neurology, the scientific journal of the American Academy of Neurology.

The study involved 18 pilots with an average age of 52. First, the pilots conducted seven practice flights on a flight simulator to train them to perform a complex series of instructions. Then half of them took the drug donepezil for 30 days and half took a placebo. They then took the flight simulator test twice more to see if they had retained the training. The pilots who had taken the drug retained the training better than those who had taken placebo did.

Researchers were testing the theory that declines in cognitive abilities due to aging are caused in part by loss of functioning of acetylcholine. Acetylcholine is a neurotransmitter that relays messages between cells in areas of the brain important for memory and thought. Donepezil is a cholinesterase inhibitor, which blocks the action of an enzyme responsible for breaking down acetylcholine.

Pilots make good test subjects because flight simulators provide reliable, objective data, according to study author Jerome Yesavage, MD, of Stanford University and the Palo Alto VA Health Care System in California.

Another reason to study the effects of aging on pilots' performance is controversy over the Federal Aviation Administration (FAA) law requiring air transport pilots to retire when they reach age 60.

"There's no shortage of opinions about what the retirement age should be," said Yesavage. "However, there's very little data to support those opinions."

Yesavage pointed out that the tasks learned in this experiment were more difficult than those experienced in routine flight operations. "So these results may not be very applicable to the retirement debate," he said.

During the 75-minute flight simulations, the pilots rece
'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
8-Jul-2002


Page: 1 2

Related medicine news :

1. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
2. Neuronal death and processing of Tau protein in Alzheimers disease
3. Researchers discover link between insulin and Alzheimers
4. New trials for counseling caregivers and patients with Alzheimers begin
5. Marijuana ingredient may stall decline from Alzheimers
6. Drugs used to treat Alzheimers in nursing homes are worsening sufferers illness
7. UT Southwestern doctors track Oklahoma Alzheimers patients via telemedicine
8. Contrary to previous findings, smoking is detrimental to patients with Alzheimers
9. Nanoscale diagnostic sets sights on Alzheimers
10. New test is first step in early detection of Alzheimers disease
11. Older people with the Alzheimers gene find it harder to remember to remember even if healthy

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Alzheimer drug improves pilots performance tests

(Date:5/24/2013)... News) -- Drugs commonly used to treat glaucoma may ... interfere with vision, according to a new study. ... used to reduce eye pressure, have already been shown ... color, the researchers said, suggesting that the new findings ... Doctors should be conservative when prescribing these drugs, the ...
(Date:5/24/2013)... Let’s face it: very few are luckily ... the majority of people to be uncomfortable with the color ... coffee addiction or simply genetics, yellowish or stained teeth suppresses ... , Herald Square Dental is proud to announce ... Venus White Max. , Teeth become discolored for a ...
(Date:5/24/2013)... Chino, CA (PRWEB) May 24, 2013 Area ... huge selection of new hot tubs to choose from at ... Super Sale . The sales event takes place at ... May 26, 2013. , Jacuzzi, the industry's leading hot ... sale traveling across the country. The event will feature popular ...
(Date:5/24/2013)... New York (PRWEB) May 24, 2013 ... lawsuit involving Intuitive Surgical Inc.’s da Vinci Surgical ... to court records, a Washington State Court jury ruled ... negligence in training a surgeon who performed a da ... later. The patient’s family had alleged in their ...
(Date:5/24/2013)... development of infantile myofibromatosis (IM)a disorder characterized by multiple ... new therapeutic targets, according to researchers from the Icahn ... in the American Journal of Human Genetics , ... disease, for which the only current treatment option is ... an inheritied disorder that develops in infancy or even ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: